• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一名患有 - 突变肺癌和弥漫性成骨性骨转移的患者中,地诺单抗诱导的严重低钙血症需要长期强化药物治疗。

Severe denosumab-induced hypocalcemia requiring long-term intensified medication in a patient with -mutant lung cancer and diffuse osteoblastic bone metastases.

作者信息

Mori Masayuki, Shirasawa Masayuki, Oguri Akihito, Yamamoto Hiroki, Manabe Hideaki, Nakahara Yoshiro, Sato Takashi, Naoki Katsuhiko

机构信息

Department of Respiratory Medicine, School of Medicine, Kitasato University, Kanagawa, Japan. Address: 1-15-1 Kitasato, Minami, Sagamihara, Kanagawa, 252-0375, Japan.

Department of Respiratory Medicine, Tachikawa Sogo Hospital, Tokyo, Japan. Address: 4-1, Midori, Tachikawa, Tokyo, 190-8578, Japan.

出版信息

Respir Med Case Rep. 2025 Feb 26;54:102183. doi: 10.1016/j.rmcr.2025.102183. eCollection 2025.

DOI:10.1016/j.rmcr.2025.102183
PMID:40104434
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11915153/
Abstract

Lung cancer often causes bone metastasis, and denosumab is administered to bone metastases to prevent bone-related adverse events. One of the important side effects of denosumab is hypocalcemia, but this is generally not a problem, as it is used with calcium supplementation. A 48-year-old non-smoker male was diagnosed with lung adenocarcinoma with EGFR L858R mutation with diffuse bone metastases. Three days after receiving denosumab, the patient developed weakness and numbness in his limbs and was diagnosed with drug-induced hypocalcemia due to denosumab. It takes more than 4 months for treating the hypocalcemia in this case with continuous intravenous infusion of calcium gluconate with oral calcium supplementation for 2 months of hospitalization and subsequent 2 months of outpatient treatment with intermittent intravenous infusion of calcium gluconate three times a week along with oral supplementation. Tartrate-resistant acid phosphatase-5b (TRACP-5b), a marker of bone resorption, was a biomarker for the required amount of calcium in this case. Patients with lung cancer with diffuse osteoblastic bone metastases could develop severe hypocalcemia and require long-term calcium supplementation.

摘要

肺癌常导致骨转移,地诺单抗用于骨转移以预防骨相关不良事件。地诺单抗的重要副作用之一是低钙血症,但这通常不是问题,因为它与钙剂补充联合使用。一名48岁不吸烟男性被诊断为伴有EGFR L858R突变的肺腺癌且有弥漫性骨转移。在接受地诺单抗治疗三天后,患者出现肢体无力和麻木,被诊断为地诺单抗所致药物性低钙血症。该病例持续静脉输注葡萄糖酸钙并口服钙剂,住院2个月,随后门诊治疗2个月,每周间歇性静脉输注葡萄糖酸钙三次并口服补充钙剂,治疗低钙血症耗时超过4个月。抗酒石酸酸性磷酸酶-5b(TRACP-5b)是骨吸收标志物,在此病例中是所需钙剂剂量的生物标志物。伴有弥漫性成骨性骨转移的肺癌患者可能发生严重低钙血症,需要长期补充钙剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f0/11915153/d84d1a352223/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f0/11915153/182b0dbbe6b7/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f0/11915153/d84d1a352223/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f0/11915153/182b0dbbe6b7/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f0/11915153/d84d1a352223/gr2.jpg

相似文献

1
Severe denosumab-induced hypocalcemia requiring long-term intensified medication in a patient with -mutant lung cancer and diffuse osteoblastic bone metastases.在一名患有 - 突变肺癌和弥漫性成骨性骨转移的患者中,地诺单抗诱导的严重低钙血症需要长期强化药物治疗。
Respir Med Case Rep. 2025 Feb 26;54:102183. doi: 10.1016/j.rmcr.2025.102183. eCollection 2025.
2
High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.高骨转换增加了绝经后骨质疏松症女性使用地诺单抗导致低钙血症的风险。
Ther Clin Risk Manag. 2016 Dec 5;12:1831-1840. doi: 10.2147/TCRM.S123172. eCollection 2016.
3
Bone turnover markers as predictors of hypocalcemia in patients with bone metastases receiving denosumab.骨转换标志物作为接受地诺单抗治疗的骨转移患者低钙血症的预测指标
JBMR Plus. 2025 Jan 21;9(4):ziaf013. doi: 10.1093/jbmrpl/ziaf013. eCollection 2025 Apr.
4
Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.肾功能受损可预测地舒单抗引起的血钙降低以及非严重肾功能不全患者的骨密度增加。
Osteoporos Int. 2019 Jan;30(1):241-249. doi: 10.1007/s00198-018-4688-1. Epub 2018 Sep 5.
5
A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.RANKL的一个问题:地诺单抗诱导的低钙血症。
J Med Toxicol. 2016 Sep;12(3):305-8. doi: 10.1007/s13181-016-0543-y. Epub 2016 Mar 17.
6
SEVERE, PROLONGED, DENOSUMAB-INDUCED HYPOCALCEMIA WITH RECOVERY AFTER 111 DAYS OF HIGH-DOSE CALCIUM SUPPLEMENTATION.严重、长期的地诺单抗诱导的低钙血症,在高剂量补钙111天后恢复
AACE Clin Case Rep. 2019 Jan 30;5(1):e82-e85. doi: 10.4158/ACCR-2018-0295. eCollection 2019 Jan-Feb.
7
Denosumab-induced hypocalcemia post bariatric surgery-a severe and protracted course: a case report.减重手术后导致的地舒单抗相关性低钙血症——严重且持久的病程:一例报告。
J Med Case Rep. 2023 Mar 2;17(1):73. doi: 10.1186/s13256-023-03764-w.
8
The relationship between chronic kidney disease and denosumab-induced hypocalcemia in high-age osteoporotic patients.高龄骨质疏松患者慢性肾脏病与地舒单抗致低钙血症的关系。
J Bone Miner Metab. 2022 Jul;40(4):670-676. doi: 10.1007/s00774-022-01331-9. Epub 2022 May 31.
9
Severe and prolonged hypocalcemia after a single dose of denosumab for metastatic breast cancer with diffuse bone involvement without prior calcium/vitamin D supplementations.转移性乳腺癌伴弥漫性骨累及患者单次使用地舒单抗后出现严重且持久的低钙血症,且无钙/维生素 D 补充。
J Oncol Pharm Pract. 2021 Jul;27(5):1287-1290. doi: 10.1177/1078155220964550. Epub 2020 Oct 21.
10
Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.地舒单抗停药后 RANKL 和 TRAcP 5b 的变化表明 RANKL 介导致破骨细胞形成导致骨吸收增加。
Osteoporos Int. 2023 Mar;34(3):599-605. doi: 10.1007/s00198-022-06651-0. Epub 2022 Dec 22.

本文引用的文献

1
Relationship between clinical features and gene mutations in non-small cell lung cancer with osteoblastic bone metastasis.非小细胞肺癌成骨型骨转移的临床特征与基因突变的关系。
Cancer Treat Res Commun. 2021;28:100440. doi: 10.1016/j.ctarc.2021.100440. Epub 2021 Jul 24.
2
Hypocalcaemia following denosumab in prostate cancer: A clinical review.地舒单抗治疗前列腺癌后低钙血症:临床综述。
Clin Endocrinol (Oxf). 2020 Jun;92(6):495-502. doi: 10.1111/cen.14169. Epub 2020 Feb 16.
3
Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol.
起始或切换用地舒单抗联合骨化三醇后血清钙水平早期变化的潜在关联。
J Bone Miner Metab. 2019 Mar;37(2):351-357. doi: 10.1007/s00774-018-0928-x. Epub 2018 May 2.
4
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
5
Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.全胃切除术后单剂量地诺单抗治疗胃癌弥漫性骨转移后出现的持续性低钙血症
Intern Med. 2017 Nov 1;56(21):2879-2882. doi: 10.2169/internalmedicine.8908-17. Epub 2017 Sep 25.
6
Hypocalcaemia in patients with metastatic bone disease treated with denosumab.伴有骨质转移的患者接受地舒单抗治疗后发生低钙血症。
Eur J Cancer. 2015 Sep;51(13):1812-21. doi: 10.1016/j.ejca.2015.05.016. Epub 2015 Jun 17.
7
Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.地诺单抗、阿仑膦酸钠或阿仑膦酸钠后用地诺单抗对去卵巢食蟹猴骨转换、钙稳态、骨量和骨强度的影响。
J Bone Miner Res. 2015 Apr;30(4):657-69. doi: 10.1002/jbmr.2401.
8
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.利用肺癌致癌驱动基因的多重分析来选择靶向药物。
JAMA. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741.
9
Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13.IIIb 期和 IV 期肺癌患者中骨转移(BM)和骨骼相关事件(SREs)发生率的前瞻性研究-CSP-HOR 13
J Thorac Oncol. 2014 Feb;9(2):231-8. doi: 10.1097/JTO.0000000000000051.
10
Identification of the risk factors associated with hypocalcemia induced by denosumab.识别与地舒单抗引起的低钙血症相关的风险因素。
Biol Pharm Bull. 2013;36(10):1622-6. doi: 10.1248/bpb.b13-00496. Epub 2013 Aug 9.